Neurology
New Book Challenges Conventional Dementia Care, Advocates for Non-Invasive Gamma Stimulation
Mark L. Fox's 'The Memory Room' presents evidence that cognitive decline may be mitigated through 40 Hz gamma stimulation, based on MIT research and a clinical study showing cognitive improvement in all 41 participants.
Study Links Traumatic Brain Injury to Higher Brain Cancer Mortality, Urging Long-Term Monitoring
A Mass General Brigham study found that traumatic brain injury increases brain cancer mortality risk, prompting calls for revised long-term care and highlighting implications for drug developers like CNS Pharmaceuticals.
National ALS Registry Seeks Participants to Unlock Disease Mysteries
The National ALS Registry, a CDC program, encourages people with ALS to enroll and complete risk factor surveys to aid research into causes and treatments, highlighting the urgent need for data to combat the disease that affects over 5,000 new Americans annually.
Low Blood Pressure Shows Strongest Link to Alzheimer's Risk in New Analysis of Nearly 800,000 Adults
A new study in the Journal of the American Heart Association finds that hypotension is most strongly associated with Alzheimer's disease among several cardiovascular conditions, with stronger effects in Black and Hispanic adults, suggesting shared biological roots.
Quantum BioPharma Completes Phase 1 Trial for Multiple Sclerosis Therapy Lucid-MS
Quantum BioPharma announces completion of Phase 1 clinical studies for Lucid-MS, a therapy targeting myelin repair in multiple sclerosis, and submission of an IND application to the FDA.
Quantum BioPharma Advances Multiple Sclerosis Therapy with LUCID-MS Program, Completes Phase 1 Trials
Quantum BioPharma has completed Phase 1 clinical studies for LUCID-MS, a therapy targeting myelin repair in multiple sclerosis, and filed an IND with the FDA, addressing the critical unmet need for neuroprotective treatments.
Quantum BioPharma Diversifies Pipeline to Address Neurological and Wellness Markets
Quantum BioPharma is advancing a novel MS therapy and expanding into alcohol health with unbuzzd, targeting unmet needs in neurological care and consumer wellness.
Quantum BioPharma Builds Diversified Pipeline Targeting Neurological and Wellness Markets
Quantum BioPharma Ltd. advances LUCID-MS for multiple sclerosis and expands into alcohol metabolism with unbuzzd, addressing unmet needs in neurology and wellness.
Quantum BioPharma Advances Multiple Sclerosis Program with Differentiated Approach
Quantum BioPharma is progressing its clinical-stage multiple sclerosis program targeting demyelination, a novel strategy distinct from immune-modulating therapies, while maintaining a diversified portfolio including consumer wellness products and sufficient capital through 2028.
NeuroOne to Present New Trigeminal Nerve Ablation System and Drug Delivery Platform at ASSFN Meeting
NeuroOne Medical Technologies will showcase its recently FDA-cleared OneRF® Trigeminal Nerve Ablation System and provide updates on its investigational SEEG-Drug Delivery System at the 2026 ASSFN Biennial Meeting, highlighting advancements in neurological surgery.
Oncotelic Therapeutics Advances CNS Drug Delivery Strategy Amid BBB Breakthroughs
Oncotelic Therapeutics' $12.5M monetization of its CNS delivery system highlights growing industry focus on blood-brain barrier bypass technologies, unlocking new biotech market opportunities.
Brain Cell Division Errors May Unlock New Cancer Treatments, Study Finds
Researchers at the University of Virginia have discovered that errors in brain cell division during development could trigger cancer and developmental disorders, offering new pathways for treatment and prevention.
Graphene Quantum Dots Show Promise in Targeting Parkinson's-Related Protein Clumping
A new study reveals that graphene quantum dots can interfere with the aggregation of misfolded proteins linked to Parkinson's disease, offering a potential new direction for therapeutic exploration.
Annovis Bio Raises $15 Million in Public Offering to Fund Neurodegenerative Disease Trials
Annovis Bio has priced a $15 million public offering of common stock and warrants, with proceeds earmarked for clinical development of its lead candidate buntanetap for Alzheimer's and Parkinson's diseases.
Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference Amid Progress in Neurological Therapeutics
Oragenics Inc. will present at the Sidoti Micro-Cap Virtual Investor Conference, highlighting its intranasal delivery platform and upcoming clinical trials for concussion treatment.
Oragenics Advances Phase IIa Concussion Trial, Eyes CNS Device Licensing
Oragenics provided a shareholder update on its Phase IIa trial of ONP-002 for concussion in Australia, plans for U.S. regulatory meetings, and a letter of intent to license a complementary CNS medical device.
Oncotelic Therapeutics Highlights CNS Drug Delivery Innovation in NetworkNewsAudio Editorial
Oncotelic Therapeutics was featured in a NetworkNewsAudio editorial discussing the challenges of the blood-brain barrier and the company's N2B delivery system, with implications for biodefense and Alzheimer's treatment.
Oncotelic’s Intranasal Brain Delivery Platform Highlighted as CNS Drug Development Gains Urgency
Oncotelic Therapeutics featured in BioMedWire editorial for its nose-to-brain delivery platform that bypasses the blood-brain barrier, with rising Alzheimer’s cases and biodefense needs driving demand for such technologies.
Oncotelic Therapeutics Highlighted in BioMedWire Editorial on CNS Drug Delivery Innovation
Oncotelic Therapeutics was featured in a BioMedWire editorial examining breakthroughs in central nervous system drug delivery, highlighting its proprietary intranasal nose-to-brain delivery platform that aims to overcome the blood-brain barrier for neurological diseases and biodefense applications.
Oncotelic Therapeutics Targets CNS Drug Delivery as Brain Therapeutics Innovation Accelerates
Oncotelic Therapeutics is leveraging its intranasal nose-to-brain delivery platform to address the challenge of delivering therapeutics across the blood-brain barrier, targeting Alzheimer's disease and biodefense applications in a rapidly evolving biopharma landscape.
CNS Drug Delivery Innovations Address Critical Bottleneck in Biotech Market
Advancements in blood-brain barrier penetration technologies, such as Oncotelic's intranasal nose-to-brain system, are unlocking significant opportunities in the biotech sector by enabling targeted CNS therapies for diseases like Alzheimer's and bolstering biodefense preparedness.
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provisional patent application.
Oragenics Signs LOI to License CardioDialysis Technology for Brain Disorders
Oragenics Inc. has signed a letter of intent to license Sigyn Therapeutics' CardioDialysis blood purification technology, aiming to combine it with its intranasal neurosteroid candidate ONP-002 for a dual-modality approach to traumatic brain injury and neurodegenerative diseases.
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer's at Fierce Biotech Week 2026
Annovis Bio CEO will present the company's multi-protein targeting strategy for Alzheimer's disease at Fierce Biotech Week 2026, highlighting buntanetap's Phase 3 trial.
Oragenics Advances Phase IIa Trial for Concussion Treatment, Targeting Data Readout by 2026
Oragenics Inc. is actively enrolling patients at a second site in its Phase IIa trial for ONP-002, a potential first-in-class treatment for concussion, with a data readout expected by end of 2026.
NeuroOne to Report Fiscal Q2 2026 Financial Results on May 12, Highlights Minimally Invasive Neurological Tech
NeuroOne Medical Technologies will announce its fiscal second quarter 2026 financial results on May 12, 2026, with a focus on its FDA-cleared electrode and ablation systems that aim to reduce hospitalizations and improve outcomes for neurological disorders.
Brain Health Shaped by Lifetime Mental, Physical, Environmental and Lifestyle Factors, New AHA Statement Says
A new American Heart Association scientific statement highlights that brain health is influenced by a range of factors across the entire lifespan, including mental health, sleep, environment, and social conditions, offering opportunities for early intervention to reduce the risk of stroke, cognitive decline, and dementia.
New Molecule Shows Promise for Glioblastoma Treatment, Clinical Trial Underway
Researchers at Brown University Health have identified a molecule that may alter glioblastoma treatment, with a clinical trial planning direct surgical delivery to the tumor.
NeuroOne Partners with University of Minnesota to Advance Targeted Epilepsy Treatment Platform
NeuroOne Medical Technologies is collaborating with the University of Minnesota to develop a brain drug delivery system that could revolutionize epilepsy treatment by delivering therapies directly to seizure sites, potentially improving efficacy while reducing side effects.
Canadian Scientists Identify Brain Cells That Fuel Glioblastoma Growth
Researchers have discovered that certain brain cells previously thought to be passive support structures actively promote glioblastoma tumor growth, potentially opening new therapeutic avenues for one of the deadliest forms of brain cancer.